Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.

To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy.

Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years).

Patients with a clinical suspicion of prostate cancer (PSA range 2. 2-11. 7, mean 6. 2) and a negative (PIRAD 1-2/5) pre-biopsy mp-MRI (pre-contrast T1, T2, diffusion-weighted and dynamic-contrast-enhanced MRI) who underwent 10-core TRUS-guided biopsy were recruited for additional mp-MRI examinations performed at 1, 2 and 6 months post biopsy. We quantified mp-MRI peripheral zone (PZ) and transition zone (TZ) normalized T2 signal intensity (nT2-SI); T1 relaxation time (T10); diffusion-weighted MRI, apparent diffusion coefficient (ADC); dynamic contrast-enhanced MRI, maximum enhancement (ME); slope of enhancement (SoE) and area-under-the-contrast-enhancement-curve at 120 s (AUC120). Significant changes in mp-MRI parameters were identified by analysis of variance with Dunnett's post testing.

Diffuse signal changes were observed post-biopsy throughout the PZ. No significant signal change occurred following biopsy within the TZ. Left and right PZ mean nT2-SI (left PZ: 5. 73, 5. 16, 4. 90 and 5. 12; right PZ: 5. 80, 5. 10, 4. 84 and 5. 05 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) and mean T10 (left PZ: 1. 02, 0. 67, 0. 78, 0. 85; right PZ: 1. 29, 0. 64, 0. 78, 0. 87 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) were reduced significantly (P

Significant PZ (but not TZ) T2 signal changes persist up to 6 months post biopsy, whereas PZ and TZ ADC is not significantly altered as early as 1 month post biopsy. Caution must be exercised when interpreting T1- and T2-weighted imaging early post biopsy, whereas ADC images are more likely to maintain clinical efficacy. Prostate Cancer and Prostatic Disease advance online publication, 21 July 2015; doi:10. 1038/pcan. 2015. 33.

Prostate cancer and prostatic diseases. 2015 Jul 21 [Epub ahead of print]

A Latifoltojar, N Dikaios, A Ridout, C Moore, R Illing, A Kirkham, S Taylor, S Halligan, D Atkinson, C Allen, M Emberton, S Punwani

Centre for Medical Imaging, University College London, London, UK. , Centre for Medical Imaging, University College London, London, UK. , Department of Urology, University College London Hospital, London, UK. , Department of Urology, University College London Hospital, London, UK. , Department of Radiology, University College London Hospital, London, UK. , Department of Radiology, University College London Hospital, London, UK. , 1] Centre for Medical Imaging, University College London, London, UK [2] Department of Radiology, University College London Hospital, London, UK. , 1] Centre for Medical Imaging, University College London, London, UK [2] Department of Radiology, University College London Hospital, London, UK. , Centre for Medical Imaging, University College London, London, UK. , Department of Radiology, University College London Hospital, London, UK. , Department of Urology, University College London Hospital, London, UK. , 1] Centre for Medical Imaging, University College London, London, UK [2] Department of Radiology, University College London Hospital, London, UK.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe